{"organizations": [], "uuid": "c909a8b9b879cde33d61901243aacb3433a6b194", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-sarepta-therapeutics-announces-pla/brief-sarepta-therapeutics-announces-plan-to-submit-a-new-drug-application-for-accelerated-approval-of-golodirsen-idUSFWN1QU0Q0", "country": "US", "domain_rank": 408, "title": "BRIEF-Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-12T13:46:00.000+02:00", "replies_count": 0, "uuid": "c909a8b9b879cde33d61901243aacb3433a6b194"}, "author": "", "url": "https://www.reuters.com/article/brief-sarepta-therapeutics-announces-pla/brief-sarepta-therapeutics-announces-plan-to-submit-a-new-drug-application-for-accelerated-approval-of-golodirsen-idUSFWN1QU0Q0", "ord_in_thread": 0, "title": "BRIEF-Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "exon", "sentiment": "none"}, {"name": "drug application for accelerated approval of golodirsen reuters", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "sarepta therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 12, 2018 / 11:46 AM / in 11 minutes BRIEF-Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen Reuters Staff 1 Min Read March 12 (Reuters) - Sarepta Therapeutics Inc: * SAREPTA THERAPEUTICS ANNOUNCES PLAN TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR ACCELERATED APPROVAL OF GOLODIRSEN (SRP-4053) IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO SKIPPING EXON 53 * SAREPTA THERAPEUTICS INC - INTENDS TO COMPLETE A ROLLING SUBMISSION OF A GOLODIRSEN NDA BY YEAR-END 2018 * SAREPTA THERAPEUTICS INC - MET WITH FDA DIVISION OF NEUROLOGY PRODUCTS IN FEBRUARY TO OBTAIN GUIDANCE ON REGULATORY PATHWAY FOR GOLODIRSEN Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-12T13:46:00.000+02:00", "crawled": "2018-03-12T14:04:51.009+02:00", "highlightTitle": ""}